v3.26.1
SEGMENT REPORTING - Schedule of Company's Reportable Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
License revenue $ 0   $ 0   $ 0 $ (70,000)
Research and development 7,393   9,319   14,396 19,825
Segment net (income) loss 9,905 $ 9,036 10,561 $ (56,542) 18,941 (45,981)
Reportable segment            
Segment Reporting [Line Items]            
License revenue 0   0   0 (70,000)
Non-program expenses 3,196   2,997   5,806 6,543
Personnel-related expenses 2,458   2,671   5,470 6,022
Other segment items (614)   (996)   (1,362) (1,219)
Segment net (income) loss 9,905   10,561   18,941 (45,981)
Reportable segment | Silevertinib (NSCLC) research and development expenses            
Segment Reporting [Line Items]            
Research and development 2,232   5,518   5,020 10,722
Reportable segment | Silevertinib (GBM) research and development expenses            
Segment Reporting [Line Items]            
Research and development 2,633   0   4,001 0
Reportable segment | BDTX-4933 research and development expenses            
Segment Reporting [Line Items]            
Research and development 0   0   0 1,018
Reportable segment | Other research programs and development expenses            
Segment Reporting [Line Items]            
Research and development $ 0   $ 371   $ 6 $ 933